Announcement • 1h
Rocket Doctor AI Inc. announced that it expects to receive CAD 2 million in funding Rocket Doctor AI Inc. to announce a proposed non-brokered private placement of unsecured convertible debentures in the amount of $1,000 each in the aggregate principal amount of up to CAD 2,000,000 on July 28, 2026. The Debentures will bear interest from the date of issuance at a rate of 12.0% per annum, calculated and payable on maturity which is 12 months following the issuance of the Debentures. The principal amount of the Debentures, together with any accrued and unpaid interest, may be converted, in whole or in part at the election of the holder, into units of the Company at a conversion price of CAD 0.70 per Unit on the earlier of: (i) the business day immediately preceding the Maturity Date; and (ii) the business day immediately preceding the date fixed for redemption of the Debentures by the Company, if any, subject to the terms therein. Each Unit will consist of one common share in the capital of the Company and one transferable Share purchase warrant (a “Warrant”), with each Warrant being exercisable into one Share (a “Warrant Share”) at an exercise price of CAD 0.75 per Warrant Share for a period of 12 months from the date of issuance pursuant to the terms therein. The Warrant Expiry Date may be accelerated in the event the Shares trade on the CSE at CAD 0.75 or more per Common Share for any 10 consecutive trading days, and, upon delivery of a notice to the holder, the Warrant Expiry Date will be accelerated to 5:00pm on the date that is 10 calendar days from the date of delivery of an acceleration notice to the holder. Closing of the Offering is subject to a number of conditions, including receipt of all necessary corporate and regulatory approvals, including that of the CSE. The securities issued in connection with the Offering will be subject to applicable statutory hold periods imposed under applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions and may close in one or more tranches. The Company anticipates paying finders' fees to eligible parties who have assisted in introducing subscribers to the Offering. Any finders' fees payable will be in accordance with the policies of the CSE. Announcement • Jul 07
Rocket Doctor Ai Inc. Announces CFO Changes Rocket Doctor AI Inc. had appointed Mr. Andrew Lau, CPA, CA as Chief Financial Officer, effective July 6, 2026. Mr. Lau brought over 18 years of capital markets, corporate finance, and public company experience to Rocket Doctor AI. Throughout his career, he had held executive finance leadership roles with high-growth technology and life sciences companies, where he had led corporate finance, treasury, financial reporting, corporate development, and public company initiatives. Mr. Lau began his career with Deloitte LLP, where he earned his Chartered Professional Accountant designation, before joining RBC Capital Markets as an investment banker specializing in M&A and equity financing transactions. Over the course of his career, he had advised on and executed more than $700 million in M&A and capital markets transactions and had played a key role in helping emerging growth companies scale, strengthen their financial operations, and access the public markets. Mr. Lau replaced Mr. Chris Cherry, who stepped down as Interim CFO to return to his role as Chair of the Audit Committee while continuing his service as a director. Live News • Jul 01
Rocket Doctor AI Secures First US Value-Based Care Deal Expanding Access for 5 Million Members Rocket Doctor AI has entered its first value-based primary care provider agreement in the US with a California independent physician association, expanding its in-network coverage to more than 5 million patients across multiple payer types under a recurring per-member-per-month model.
The deal gives Rocket Doctor AI a foothold in California and shifts a portion of its business toward value-based care, with an emphasis on continuity of care, preventive health and long-term patient outcomes, which could influence how revenue is earned and recognized.
Rocket Doctor AI shares last traded at CA$0.60, with the stock down 26.8% year to date.
This move introduces a recurring revenue framework tied to patient panels rather than one-off visits. This structure can change both growth potential and execution risk, particularly around care quality, cost control and relationship management with payers and physicians. Announcement • Jun 17
Treatment.Com Inc Receives Year 2 Funding from National Institute on Minority Health and Health Disparities Rocket Doctor AI Inc. announced that Treatment.com Inc., in collaboration with Rush River Research, had received confirmation of second-year funding from the National Institute on Minority Health and Health Disparities, part of the National Institutes of Health. The funding granted follows the successful completion of the program’s first-year milestones and extends support for the development of an AI-powered family medical history tool designed to make preventive care more accurate, accessible, and culturally responsive. The second-year award provides Treatment with in excess of USD 250,000 in additional support, with the program agreement now extended through May 31, 2027. This extension provides Treatment with over USD 500,000 to enhance its Global Library of Medicine and AI-powered clinical tools. The two-year project is supported by a highly competitive Small Business Innovation Research grant with a total award value of approximately USD 2 million. As part of the Year 2 extension, Treatment will receive more than USD 250,000 in additional funding, bringing its total program support to more than USD 500,000. The project agreement now extends through May 31, 2027. New Risk • May 24
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 30% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Shareholders have been substantially diluted in the past year (30% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$55.2m market cap, or US$39.9m). Announcement • Jan 23
Rocket Doctor AI Inc. announced that it has received CAD 5.2 million in funding On January 22, 2026,Rocket Doctor AI Inc. closed the transaction. In connection with the closing of the transaction, the company paid to certain finders cash commission of CAD 198,800 and issued 284,000 non-transferrable warrants of the Company exercisable at any time until January 22, 2027 to acquire one Common Share at an exercise price of CAD 0.85, subject to adjustment in certain events. The securities issued in the Offering are not subject to a hold period in accordance with applicable Canadian securities laws. Announcement • Dec 09
Rocket Doctor AI, Health Cities and CAN Health Network Partner to Advance AI-Powered Clinical Decision Support in Alberta Rocket Doctor AI Inc. announced a new partnership with the CAN Health Network to test its AI-powered Clinical Decision Support System (CDSS) in collaboration with Health Cities. The project will launch at up to four primary care sites in Alberta to help physicians deliver faster, evidence-based, and more efficient care. The program was developed in accordance with Health Cities' need for an integrated, AI-powered solution capable of analyzing diverse data sources, automating routine tasks, and delivering real-time clinical recommendations. The project, running from November 2025 to March 2026, involves approximately 20 clinicians and aims to set the foundation for a potential full provincial rollout in 2026. As a CAN Health Network Primary Care Edge, Health Cities creates an environment where innovative solutions can be co-developed, validated, and adopted to address real-world health challenges. The initiative rolls out in three phases, beginning with AI-powered patient intake through a website-embedded chatbot, followed by real-time clinician support during visits, and ultimately integration with electronic medical records (EMRs). Rocket Doctor AI's Global Library of Medicine (GLM) is a clinically-validated decision engine developed with input from hundreds of physicians to assist providers with triage, differential diagnosis, and evidence-based care planning. This project comes at a critical time for Alberta's healthcare system, where staffing shortages, limited access to primary care, and increasing patient loads continue to strain clinics across the province. Recent data shows that one in five Albertans lacks a family physician, with many communities facing long wait times for basic care. This project aims to directly address these challenges by supporting clinicians with intelligent, AI-driven tools that improve efficiency and patient access. Key anticipated outcomes include a 25-40% reduction in physician intake time, as well as improved patient satisfaction through faster and clearer communication. The CDSS is also expected to significantly reduce physicians' administrative workload, including less time on charting, documentation, and billing. Rocket Doctor AI's platform will be hosted in secure, Canadian-based data centres, aligned with HIPAA, PIPEDA, and Alberta's Health Information Act (HIA). The modular system architecture ensures future growth, with the capability to scale across Alberta's 4,400 providers and beyond. This project is made possible through funding and support from the CAN Health Network, a federally funded initiative designed to help Canadian companies scale innovative healthcare solutions domestically. The partnership underscores Rocket Doctor AI's commitment to advancing equitable access to care, supporting overburdened clinicians, and modernizing healthcare delivery through responsible AI innovation. A Commercialization Project Agreement was entered into by the parties on 12th November 2025. The Agreement details the intent of the parties to collaborate in jointly delivering a Commercialization Project. Either party may propose amendments or terminate this Agreement upon written notice. Announcement • Dec 06
Rocket Doctor AI Inc. Announces Change of Chief Financial Officer, Effective December 8, 2025 Rocket Doctor AI Inc. announced that Christopher Cherry shall assume the role of Interim Chief Financial Officer, to replace David Worner, effective December 8, 2025. Mr. Cherry is currently the Company’s Chair of the Audit Committee. Announcement • Sep 10
Rocket Doctor AI Inc., Annual General Meeting, Oct 22, 2025 Rocket Doctor AI Inc., Annual General Meeting, Oct 22, 2025. Announcement • Sep 04
Rocket Doctor Is Now In-Network for Aetna in New York State for Medicare and Commercial Health Insurance Rocket Doctor AI Inc. announced that doctors using its wholly-owned digital health platform and marketplace, Rocket Doctor Inc., are now in-network with Aetna in New York State, having been fully credentialed for Medicare and commercial plans. This milestone expands Rocket Doctor's ability to provide in-network care to Aetna members throughout the state. By combining urgent care, primary care and mental health, alongside connected medical devices and proprietary software, Rocket Doctor delivers high-quality care virtually that is both affordable and accessible, especially for patients on Medicaid and Medicare, and in rural and underserved communities. Rocket Doctor's programs include urgent care, chronic disease management, preventive health and mental health services, enabling patients to see licensed physicians from home. With in-network status, Aetna members in New York can access these services with lower out-of-pocket costs and greater convenience. Rocket Doctor is also active in New York through its partnership with EngageWell IPA and the CVS Health Foundation, which launched the Healthy Aging Program earlier this year. The pilot initiative provides free, virtual health screenings for adults over 60 in New York City, including assessments for heart health, cognitive function and mental health, along with personalized follow-up support from community health workers. The program, backed by $1 million in CVS Health Foundation funding, is designed to help older adults age with confidence, care and convenience. Rocket Doctor AI continues to expand its payer and health system partnerships across North America. The Options are each exercisable for one common share of the Company at an exercise price of CAD 0.67 per share for a period of three years from the grant date and vest over a one-year term. The RSUs are valid for a term of three years and vest over a one- year. The Options and RSUs are subject to the terms of the Company's equity plans and applicable securities law hold periods. Announcement • Aug 22
Rocket Doctor AI Inc. announced that it has received CAD 4.2347 million in funding On August 21, 2025, Rocket Doctor AI Inc. closed the oversubscribed transaction. The company issued 3,677,400 special warrants at an issue price of CAD 0.50 per special warrant for gross proceeds of CAD 1,838,700 and 4,792,000 units at an issue price of CAD 0.50 per unit for gross proceeds of CAD 2,396,000 for aggregate gross proceeds of CAD 4,234,700. Each unit is comprised of one common share of the company and one share purchase warrant of the company, with each warrant exercisable into one share at an exercise price of CAD 0.75 for 12 months from the date of issuance of the warrants. Each special warrant will automatically convert, for no additional consideration, into one unit. No special warrants may be exercised by the holder thereof prior to the conversion date. In connection with the offering, the company has paid finder’s fees totaling CAD 201,616 and issued an aggregate of 403,232 non-transferable broker warrants to arm’s-length parties. Each broker warrant entitles the holder to purchase one share at an exercise price of CAD 0.75 per share for a period of 12 months from the date of issuance of the broker warrants. The special warrants and the securities issuable upon conversion of the special warrants are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The units issued and the broker warrants, including the securities issuable thereunder, are subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. Board Change • Aug 19
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Chris Cherry was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Jul 26
Treatment.com AI Inc. announced that it expects to receive CAD 3 million in funding Treatment.com AI Inc. has announced a non-brokered private placement to issue special warrants of the company at a price of CAD 0.50 per warrant and Units of the company at a price of CAD 0.5 per Unit for gross proceeds of up to CAD 3 million on July 25, 2025. Each unit shall consist of one common share and one common share purchase warrant. Each warrant shall entitle the holder thereof to acquire one Share at a price of CAD 0.75 per Share for a period of 12 months following the date of issuance of the warrants. The Special warrants will be convertible into Units of the company. The Company may pay a finder’s fee of up to 8% of the gross proceeds of the offering and may issue to certain eligible finders non-transferable broker warrants equal up to 8% of the number of special warrants and/or units sold under the offering. Each Broker Warrant will entitle the holder to purchase one Share at a price of CAD 0.75 per Broker Share for a period of 12 months from the date of issuance. The transaction is expected to close on August 18, 2025. All the securities issued under the offering is subject to a lock up period of four months and one day from the date of issuance. New Risk • Jun 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2023 fiscal period end). Shareholders have been substantially diluted in the past year (92% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$27.9m market cap, or US$20.4m). Announcement • Jun 11
Treatment.com AI Inc. Announces New Medical Education Suite to Enhance Clinical Skills Training Through AI-Simulated Patients Treatment.com AI Inc. announced that it has released its latest version of the Medical Education Suite (MES). The University of Minnesota Medical School has successfully completed a live deployment of Treatment.com AI's new Medical Education Suite (MES), an AI-powered clinical skills assessment platform designed to support medical schools in delivering scalable, rigorous, and cost-effective Objective Structured Clinical Examinations (OSCEs). The deployment, conducted with over 240 third-year medical students, marked the first large-scale implementation of computer-simulated patient cases developed through the Global Library of Medicine (GLM), a clinician-built medical knowledge engine. The exams ran with complete technical reliability during deployment, as well as integrating seamlessly into the school's existing OSCE workflow. The MES is a scalable platform designed to reduce administrative and faculty time, improve objectivity, increase evaluation consistency, and provide a robust digital infrastructure to support both live and AI-simulated formats. The focus of the platform is to help enhance the clinical skills of next generation of healthcare professionals. By incorporating curated AI-generated cases and the supportive services provided by Treatment, the system enables: Significant reduction in faculty preparation and administrative workload. Real-time scoring that aligns directly with clinical learning objectives. Objective student evaluations with built-in educational and remediation support. Alignment with LCME standards. Secure and scalable exam delivery on campus or remotely. The University of Minnesota has calculated their Administrative cost savings ~ 40%. The MES combines AI-simulated patients with automated feedback, helping faculty assess diagnostic and management reasoning, clinical prioritization, and documentation quality, all mapped to learning objectives. Early feedback suggests that the platform enhances the student learning experience and strengthens the reliability of OSCE results. Preliminary results of the accuracy and precision of the GLM as applied in the MES platform were presented at the AAMC's 2025 Group on Information Resources meeting. Prof. Violato, Dr. Peterson, and their respective teams are preparing further scientific publications detailing the methodology, deployment, and outcomes of the UMN program. Treatment.com AI is engaging with a wide variety of other schools, with the goal to extend the MES offering across North America, the UK, and to other international OSCE markets. Announcement • Apr 10
Treatment.com AI Inc. (CNSX:TRUE) completed the acquisition of 100% shares in Rocket Doctor Inc. Treatment.com AI Inc. (CNSX:TRUE) entered into a definitive agreement to acquire 100% shares in Rocket Doctor Inc. for CAD 21.5 million on February 11, 2025. As part of consideration, Treatment.com would pay Rocket Doctor Inc (i) common shares of Treatment.com with a fair market value of $7,688,640 (CAD 11,008,749) payable on closing of the Proposed Transaction and (ii) subject to the achievement of certain 12 and 24 month milestones, additional common shares of Treatment with a fair market value of up to $6,902,560 (CAD 9,883,223) payable to the holders of SAFEs and shareholders of Rocket Doctor. In connection with the Proposed Transaction, by virtue of acquiring Rocket Doctor, Treatment.com AI Inc. will be assuming approximately CAD 627,000 in long term liabilities of Rocket Doctor.
The Transaction is subject to a number of conditions, including the receipt of regulatory approvals and approval of the CSE.
Treatment.com AI Inc. (CNSX:TRUE) completed the acquisition of 100% shares in Rocket Doctor Inc. on April 10, 2025. New Risk • Mar 30
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$25.7m market cap, or US$18.0m). New Risk • Mar 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 46% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$665k). Shareholders have been substantially diluted in the past year (46% increase in shares outstanding). Revenue is less than US$1m (CA$38k revenue, or US$27k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (CA$24.5m market cap, or US$17.0m). Announcement • Mar 14
Treatment.com AI Inc. announced that it has received CAD 3.3 million in funding On March 13, 2025, Treatment.com AI Inc. closed the transaction. Announcement • Feb 28
Treatment.com AI Inc. announced that it expects to receive CAD 3 million in funding Treatment.com AI Inc. announced that it has entered into an agreement with Ventum Financial Corp.as underwriter and sole bookrunner in connection with a brokered private placement of 6,000,000 units at a price of CAD 0.50 per Unit for gross proceeds to the Company of CAD 3,000,000 on February 27, 2025. Each Unit will consist of one common share and one-half of one Common Share purchase warrant. Each Warrant will entitle the holder thereof to purchase one Common Share of the Company for a period of 24 months following the Closing Date at an exercise price of CAD 0.75 per Warrant Share. . The Units issued pursuant to the Offering will not be subject to a hold period in accordance with applicable Canadian securities laws. Upon closing of the Offering, the Company will pay to the Underwriter a cash fee equal to 8.0% of the aggregate gross proceeds of the Offering and issue to the Underwriter warrants exercisable at any time prior to the date that is 24 months from the Closing Date to acquire that number of Units equal to 8.0% of the number of Units issued under the Offering, at an exercise price equal to the Offering Price, subject to adjustment in certain events. The Offering may close in tranches. The Offering is expected to close on or before March 12, 2025. The Offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. Announcement • Feb 13
Treatment.com AI Inc. (CNSX:TRUE) entered into a definitive agreement to acquire Rocket Doctor Inc. for CAD 20.89 million. Treatment.com AI Inc. (CNSX:TRUE) entered into a definitive agreement to acquire Rocket Doctor Inc. for CAD 20.89 million on February 12, 2025. As part of consideration, Treatment.com would pay Rocket Doctor Inc (i) common shares of Treatment.com with a fair market value of CAD 11.008749 ($7,688,640) payable on closing of the Proposed Transaction and (ii) subject to the achievement of certain 12 and 24 month milestones, additional common shares of Treatment with a fair market value of up to CAD 9.883223 ($6,902,560) payable to the holders of SAFEs and shareholders of Rocket Doctor. In connection with the Proposed Transaction, by virtue of acquiring Rocket Doctor, Treatment.com AI Inc. will be assuming approximately $542,000 in long term liabilities of Rocket Doctor.
The Transaction is subject to a number of conditions, including the receipt of regulatory approvals and approval of the CSE. New Risk • Jan 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$665k). Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Revenue is less than US$1m (CA$38k revenue, or US$27k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (CA$37.2m market cap, or US$26.0m). New Risk • Nov 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$665k). Revenue is less than US$1m (CA$38k revenue, or US$27k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Shareholders have been diluted in the past year (32% increase in shares outstanding). Market cap is less than US$100m (CA$27.4m market cap, or US$19.4m). Announcement • Nov 05
Treatment.com AI Inc. Announces Launch of its Updated Medical Education Suite Treatment.com AI Inc. announced the launch of its updated Medical Education Suite (MES) to coincide with Treatment’s participation in a landmark Symposium on AI Assessment in Medical Education being hosted by the University of Minnesota Medical School on 1st November 2024. It is estimated that over 80 countries globally have now adopted the OSCE (Objective Structured Clinical Examination) for assessing the practical clinical skills of medical students. It is estimated that between 200,000 and 300,000 medical students globally take the OSCE exam each year, as derived from indicative numbers of students from key professional bodies including: https://www.aamc.org/; https://www.uems.eu/; https://www.nmc.org.in/; Education – GMC (gmc-uk.org). As announced in a previous 2024 Press Releases,Treatment has been working diligently through 2024 to further evolve the Medical Education Suite (MES), powered by its proprietary Global Library of Medicine (GLM). The goal of furthering enhancements to the platform is the recognition that AI can be used even more effectively to reduce the administrative overhead and costs to schools in running OSCEs, as well providing greater support to medical students, thereby helping to optimize their clinical reasoning skills. Treatment’s service comprises of using its Global Library of Medicine platform (GLM) in (i) creating cases for the OSCE exams (ii) producing scripts for actors playing the role of patients (iii) scoring the exams with its proprietary automated marking platform and (iv) providing instant results to both faculty and students, as well as offering student enrichment plans. As part of this Release, Treatment is announcing the following additions to its portfolio: AI Patient – utilizing AI and a library of test Cases to further support students in their preparation and readiness for medical multiple-choice questions (MCQ’s) and OSCE exams. Objective Structured Clinical Examination (OSCE) Case Packages – the company is extending the number of test Cases provided from an initial 12 cases. These will be available in packs to schools and a planned library of up to 100 cases through fourth quarter 2024. AI Prep Tool – the platform provides students with both a “guided” and “non-guided” support to learning. The “guided” approach provides students with learning support and reasoning, whereas the “non-guided” supports enables students to simulate exam conditions. Together with the launch of its updated Medical Education Suite, Treatment is a lead participant in a Symposium on AI Assessment in Medical Education held on November 1, 2024 at the University of Minnesota Medical School, Office of Assessment and Evaluation. The creator of the Symposium, Dr. Claudio Violato described the event as a “landmark symposium”. This academic Symposium includes more than fifty medical schools, thought leaders and national education examiners from across the US, as well as international representation. Presenters include Mayo Clinic, University of Alberta as well as Treatment’s Chief Medical Officer Kevin Peterson, MD, MPH, who will be a keynote speaker, as an acknowledged leader in medical education and its utilization of AI. Treatment will continue to build out its Medical Education Suite through the rest of 2024 and early 2025. Further planned developments include: AI Doctor in a Pocket – delivers a mobile friendly AI powered clinical decision support tool for healthcare professionals and students when they are in clinics, residency or on a hospital ward. Audio/Video Analysis – using AI and the Global Library of Medicine to undertake Audio/Visual analysis which captures and transcribes the patient assessment. In addition, this will allow for behavioral analysis as part of exam scoring, as well as supporting the generation of a medical note. Announcement • Jul 31
Treatment.com AI Announces AI Pharmacy Assistant Treatment.com AI Inc. announced a new solution, AI Pharmacy Assistant designed to support pharmacists. Pharmacists are playing an increasing role in the provision of clinical decision support services, given the increasing number of people without a GP and/or the time taken to book appointments. This is representative of similar trends being seen across Canada, UK and emerging legislation in the US, all of which will lead to extending the role for pharmacists within the healthcare continuum of care. Globally, pharmacists will play a significant role in alleviating the shortages of healthcare professionals, timeliness of patient support and mitigating the financial pressures prevalent in today's healthcare systems. For many people, especially in underserved communities, the pharmacist is often the only healthcare professional people see. Therefore, providing these pharmacists with the tools and confidence to administer a wider range of services, has a positive impact for them and the wellbeing of their communities. Working with pharmacists, Treatment is excited to be announcing its new AI Pharmacy Assistant solution for pharmacists, expected to launch later in 2024. The solution is underpinned by Treatment's AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library. The GLM has been created with hundreds of credentialled clinicians globally to ensure the highest qualified clinical information and support to all healthcare professionals. AI Pharmacy Assistant will be either accessible on a patient's mobile device or through a kiosk tablet at the pharmacy. It will support pharmacists in multiple ways: Reducing the time to take patient histories and symptoms using Treatment's GLM; Automatically document all interactions with patients providing an audit trail; Extending confidence and support in expanded diagnostic support provided to patients; Minimize the risk of errors and increase clinical efficiency; Providing comprehensive diagnostic and symptom information backed by the most reliable and up-to-date medical research. The global clinical decision support systems (CDSS) market is projected to grow significantly, reaching approximately $4.05 billion by 2029 from $2.46 billion in 2024, driven by technological advancements and the integration of AI and machine learning in healthcare decision-making processes. Whilst there is a clear desire to expand the pharmacist's scope of practice, there is also a huge shortage of pharmacists globally. Therefore, pharmacists are being stretched at both ends: more work, less staff. Supportive and accurate support tools which can be trusted, such as Treatment's AI Pharmacy Assistant, will be a pivotal part of the solution. New Risk • Jun 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$665k). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (492% increase in shares outstanding). Revenue is less than US$1m (CA$38k revenue, or US$28k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Market cap is less than US$100m (CA$14.5m market cap, or US$10.6m). Announcement • May 09
Treatment.com AI Inc. Announces Appointment of Richard Atkins as Chief Operating Officer and Executive Team Member Treatment.com AI Inc. announced the appointment of Richard Atkins as Chief Operating Officer and a member of the executive team. Mr. Atkins brings to the business a successful career with over 30 years’ experience in international sales, partnerships, executive management and M&A, highlighted by multiple multi-million dollar deals working with both major health-tech and software corporations. Mr. Atkins spent his formative career in software and technology including: networking, managed services, data centers & virtualization, omnichannel contact centers, CRM, enterprise search/data analytics, cloud-based applications. However, for the past 15 years, he has brought his experience to healthcare, working across the continuum of care, with a focus on clinical decision support. His experience spans innovative international physical and mental health solutions including: Digital Health - healthbots, symptom checkers, telehealth, Alexa voice and social media solutions, National/Provincial teletriage services, Managed PACS/RIS and LIM services in both public/private sectors, EMR/Billing and HL7/FHIR interoperability. His experience includes multi-million dollar contracts with the NHS (England and Scotland); national/regional triage services in Australia, Europe and North America; building out formative triage services in Africa through to working with US based Health Navigator (acquired by Amazon Care in 2019). Announcement • May 08
Treatment.com AI Inc., Annual General Meeting, Jul 08, 2024 Treatment.com AI Inc., Annual General Meeting, Jul 08, 2024. Announcement • Apr 17
Treatment.com AI Inc. Announces New Additions to Its Medical Education Suite (MES) Treatment.com AI Inc. announced two new solutions, (1) AI Patient and (2) AI Doctor in a Pocket, to augment its Medical Education Suite ("MES") designed to educate the next generation of healthcare providers. Treatment's MES enhances the entire continuum of clinical content education, from simple introductory patient interactions to more advanced USMLE diagnostic evaluations and grading to complex faculty benchmarking. It is designed to reduce faculty administration costs and time, provide a comprehensive range of clinical experiences, and offer students a digital self-test companion to enhance their understanding of diagnostic clinical approaches. The suite of solutions provides support for faculty and students in both design and preparation for the OSCE (Objective Structured Clinical examination). This established clinical exam is used in 57 countries to test the practical reasoning of healthcare professional students and measure their progress in clinical diagnosis and treatment. The market in the US alone comprises 300 medical schools; 900 nursing schools;227,000 students and 145,000 residents/medical students. Treatment is also in discussions with schools in the UK and Canada. Treatment is excited to be announcing two new monthly subscription-based SaaS solutions for students, residents and all healthcare professionals expected to launch in the second half of 2024: AI Patient - utilizing AI and a library of test cases to further support students in their preparation and readiness for medical multiple-choice questions (MCQ's) and OSCE exams; AIDoctor in a Pocket - delivers a mobile friendly AI powered clinical decision support tool for healthcare professionals and students when they are in clinics or on a ward. Both solutions are underpinned by Treatment's AI powered proprietary Global Library of Medicine (GLM), the most comprehensive and integrated online medical library. The GLM has been created with hundreds of credentialled clinicians globally to ensure the highest qualified clinical information and support to all healthcare professionals. New Risk • Mar 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$2.7m). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (475% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (CA$19.4m market cap, or US$14.4m). Announcement • Mar 15
Treatment.com AI Inc. announced that it has received CAD 2.9082 million in funding On March 14, 2024, Treatment.com AI Inc. closed the transaction. The company issued 6,295,500 special warrants at a price of CAD 0.40 per special warrant for gross proceeds of CAD 2,518,200; and 975,000 units at a price of CAD 0.40 per unit for gross proceeds of CAD 390,000; for aggregate gross proceeds of CAD 2,908,200 in the transaction. Each unit is comprised of one common share and one-half of one share purchase warrant, with each warrant exercisable into one additional share at an exercise price of CAD 0.60 for two years from the date of closing. The company has paid finder’s fees totaling CAD 220,816 and issued an aggregate 552,040 non-transferable broker warrants to arm’s-length parties. Each broker warrant entitles the holder to purchase one common share at an exercise price of CAD 0.60 per broker share for a period of two years from the date of closing. Announcement • Feb 18
Treatment.com AI Inc. announced that it expects to receive CAD 2 million in funding Treatment.com AI Inc. announced a non-brokered private placement to issue up to 5,000,000 special warrants at a price of CAD 0.4 per warrant for the gross proceeds of up to CAD 2,000,000 on February 16, 2024. Each Special Warrant will automatically convert without payment of any additional consideration into one unit of the company on the date that is the earlier of the third business day after a) a receipt for a final prospectus; the date of filing a prospectus supplement to a short form base shelf prospectus qualifying the distribution of the Shares and Warrants issuable upon the conversion of the Special Warrants and 4 months and one day after the issue date of the Special Warrants. Each Unit will be comprised of one common share of the Company and one-half of one share purchase warrant of the Company, with each Warrant exercisable into one additional share at an exercise price of CAD 0.60 for 2 years from the date of closing. The Company may pay a finder's fee of up to 8% of the gross proceeds of the Offering and may issue to certain eligible finders non-transferable broker warrants equal up to 8% of the number of Special Warrants sold under the offering. The Offering is expected to close on or before February 29, 2024. The offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The Offering is not subject to a minimum aggregate amount of subscriptions. New Risk • Dec 12
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (38% average weekly change). Negative equity (-CA$2.5m). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (460% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (CA$18.2m market cap, or US$13.4m). Board Change • Oct 22
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Chris Cherry was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Oct 07
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 423% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-CA$2.5m). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (423% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (CA$7.79m market cap, or US$5.70m). Announcement • Oct 06
Treatment.Com International Inc. announced that it has received CAD 0.37125 million in funding On October 5, 2023, Treatment.Com International Inc. closed the transaction. The company amended the terms of the transaction and issued 2,475,000 common shares in the capital of the company at a price of CAD 0.15 per common share, for aggregate gross proceeds of up to CAD 371,250. Announcement • Oct 01
Treatment.Com International Inc. announced that it has received CAD 1 million in funding On September 29, 2023, Treatment.Com International Inc. closed the transaction. The company paid finder's fee in cash of CAD 17,500 and 175,000 non-transferable share purchase warrants. Each finder's warrant entitles the holder thereof to acquire one common share at a price of CAD 0.255 per common share until September 29, 2025. Announcement • Sep 29
Treatment.Com International Inc. announced that it expects to receive CAD 0.5 million in funding Treatment.Com International Inc. announced a non-brokered private placement of up to 3,333,333 common shares in the capital of the company at a price of CAD 0.15 per common share, for aggregate gross proceeds of up to CAD 500,000 on September 29, 2023. The offering is expected to close on or before October 10, 2023. The offering is subject to certain conditions including, but not limited to, receipt of all necessary approvals including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a statutory hold period of four months plus one day from the date of issuance in accordance with applicable securities legislation. The offering is not subject to a minimum aggregate amount of subscriptions. Announcement • Aug 18
Treatment.Com International Inc. announced that it expects to receive CAD 1 million in funding Treatment.Com International Inc. announced a private placement of 10,000,000 common shares at a price of CAD 0.10 per share for the gross proceeds of CAD 1 million on August 18, 2023. Closing of the transaction is subject to the Canadian Securities Exchange approval and shareholder's approval pursuant to the policies of the Canadian Securities Exchange. No finder's fees is payable in connection with the transaction. Announcement • May 19
Treatment.Com International Inc. Announces CEO Changes Treatment.com International Inc. announced the resignation of Dr. Paul A. Markham as Chief Executive Officer of the Company. Mr. Kevin Peterson, Chair of the Board, shall assume the role as Interim Chief Executive Officer. Board Change • May 31
High number of new directors Independent Director Chris Cherry was the last director to join the board, commencing their role in 2021. Announcement • May 20
Treatment.Com International Inc. announced that it has received CAD 0.34 million in funding Treatment.Com International Inc. announced a non-brokered private placement of 400 unsecured convertible debentures at a price of CAD 850 per debenture for gross proceeds of CAD 340,000 on May 18, 2022. The debentures were issued at a discount of 15%. The debentures bear interest at a rate of 8.00% per annum, accruing on a semi-annual basis and payable, in cash or units of the company, every 6 months from the date of issue, maturing 24 months from the date of issue. Each unit will consist of one common share in the capital and one transferable share purchase warrant with each warrant being exercisable into one share at a price of CAD 0.50 per warrant share for a period of two years following the issue date. The principal amount of CAD 400,000 is convertible, at the option of the holder, into units at a conversion price equal to CAD 0.41 per unit at any time following the issue date until the earlier of the business day immediately preceding the maturity date, being May 17, 2024; and the business day immediately preceding the date fixed for redemption of the debentures by the company. The company will pay a finders fee of CAD 1,700. The debentures and the units issuable thereunder are subject to a statutory hold period of four months and one day commencing on closing. Board Change • Apr 27
High number of new directors Independent Director Chris Cherry was the last director to join the board, commencing their role in 2021. Announcement • Apr 08
Treatment's Debut AI-Driven Health App Getting Five Star Reviews from Doctors Treatment.Com International Inc. announced it's landmark debut product, Treatment Digital Health App, has been garnering five-star reviews on both the Apple App Store and the Google Play Store. Users' comments have been resoundingly positive about both the comprehensive nature of the assessment, as well as the accuracy of the assessment results. Reviews have come directly from medical doctors in the US, and state that Treatment's much-anticipated app is "is living up to my high expectations; and, equally importantly, does not have the concerns (including inaccuracies and trying to replace physicians) that I had feared. Announcement • Mar 29
Treatment.Com International Inc. announced that it expects to receive CAD 1.25 million in funding Treatment.Com International Inc. announced a non-brokered private placement of 1,250,000 unsecured convertible debentures for CAD 1 per debenture for gross proceeds of up to CAD 1,250,000 on March 28, 2022. Each debenture will consist of a CAD 1 principal amount of unsecured, non-redeemable 8% convertible debentures, maturing 36 months from issuance, and convertible at the option of the debenture holder into units at the company at a conversion price of CAD 0.41 per unit. Upon conversion, each unit will be comprised of one common share and one common share purchase warrant, each warrant exercisable at a price of CAD 0.50 for a period of two years from issuance. Interest at a rate of 8% per annum will be paid to debenture holders monthly in arrears. At the election of the company, interest may be paid in units of the company issued at the prevailing market price of the company’s common shares at the time of election by the company. The company may pay finders’ fees in connection with the private placement. In addition to the statutory hold period as required under securities laws, the units issuable upon conversion of the debentures will be subject to a contractual hold period of twelve months from closing. Announcement • Feb 18
Treatment.Com International Inc. Develops A Next-Generation Ai Platform to Help Patients and Caregivers Around the World Make Better Health Decisions Treatment.Com International Inc. has developed a next-generation AI platform to help patients and caregivers around the world make better health decisions. After a successful launch on the Apple App Store, Treatment’s revolutionary symptom assessment tool, Treatment Digital Health App, is now available to millions more smartphone users through the Google Play Store. Powered by Treatment’s proprietary medical AI engine and their Global Library of Medicine (GLM), the Treatment Digital Health App provides the most advanced access to medical knowledge ever available for widespread use. The Treatment Digital Health App’s health assessments go beyond what users might find through a typical online search, as the results are generated using up-to-date estimates of disease rates, current estimates of geographic variation, and the latest medical research. Doctors around the world currently trust Treatment’s AI software to provide information for their clinical assessments, and the same technology is used by leading medical schools to test students’ clinical skills. Now, even more users will have access to the same technology through the Treatment Digital Health App. The Treatment Digital Health App is available worldwide on the Apple App Store and the Google Play Store. Announcement • Jan 25
Treatment.Com International Inc. Launches Doctor Built Digital Health App Treatment.Com International Inc. announced the global launch of its much-anticipated Treatment Digital Health App, now available in the Apple App Store. The Treatment Digital Health App is a revolutionary symptom assessment tool, built and continually updated by a global team of doctors and engineers to provide users with highly predictive and accurate insights about their health. Powered by Treatment’s proprietary medical AI engine and their Global Library of Medicine (GLM), the Treatment Digital Health App provides the most advanced access to medical knowledge ever available for widespread use. The Treatment Digital Health App’s health assessments go beyond what users might find through a typical online search, as the results are generated using up-to-date estimates of disease rates, current estimates of geographic variation, and the latest medical research. Doctors around the world currently trust Treatment’s AI software to provide information for their clinical assessments, and the same technology is used by leading medical schools to test students’ clinical skills. Now, Treatment Digital Health App users have access to the same technology. At the heart of the Treatment Digital Health App sits Treatment’s innovative Global Library of Medicine (GLM) and their powerful AI engine -- together, these form an advanced, scalable medical intelligence platform providing global diagnoses and treatment protocols that can be tailored to accommodate local needs. “The probability-based symptom evaluation provided by the Treatment platform supports multiple products that can promote prevention, ensure quality, improve safety, reduce unnecessary costs, and improve decisions, all of which leads to better overall healthcare outcomes,” says Kevin Peterson, Chief Medical Officer of Treatment. Board Change • Dec 06
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Chief Medical Officer & Chairman Kevin Peterson is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Announcement • Jun 18
Treatment.Com International Inc. announced that it has received CAD 5.004 million in funding On June 17, 2021, Treatment.Com International Inc. (CNSX:TRUE) closed the transaction. The Company has paid finder's fees of CAD 185,140 and issued 36,880 finder's warrants to arm's-length parties. Each Finders Warrant is exercisable into one common share at a price of CAD 5 per share, for a period of 18 months. All securities issued pursuant to the Private Placement will be subject to a hold period expiring October 18, 2021. Announcement • May 21
Treatment.Com International Inc. Develops an Ai Platform to Help Make Better Health Decisions Treatment.Com International Inc. has developed an AI platform to help make better health decisions. Treatment is launching their first product, Cara.Health that will leverage the proprietary AI to provide health insights and health management in a supportive digital tool. 1 billion consumers turn to Google everyday to look up a health question. The results are not personalized or considerate of their health history, and can lead to confusion and fear. Cara’s AI takes into account each individual’s health profile and their symptoms to provide a more accurate and personalized recommendation about what they might have. Cara’s AI technology will provide intelligent follow up to the consumer to ensure they are getting the healthcare support and management they need. The AI engine builds a unique health profile around each individual by pulling in a multitude of data inputs, including wearable smart technology and other digital healthcare monitoring and tracking apps. The Cara mobile app is powered by a next-generation AI software engine that was developed by a global team of doctors over the last 5 years. Paired with the ability to track, monitor and follow up with every user, and their family members, the Cara app is designed to truly help put healthcare power in the patient’s hands. 
